Načítá se...
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms
The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: al...
Uloženo v:
| Vydáno v: | Expert Rev Anticancer Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5176249/ https://ncbi.nlm.nih.gov/pubmed/19445582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.09.14 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|